Category Archives: Journal Club #02: Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis

Statistics and Metrics from 2nd #RheumJC

Some analysis for round 2 of #RheumJC

Overall (combined sessions and time between and after) there were 46 total participants

  • 20 people had participated in last month’s journal club (round 1)
  • 26 people were new
  • 17 different countries were represented

Compared to last month, there were 10 fewer total participants

  • The total number of rheumatologists stayed the same (26 in round 1, 25 in round 2)
  • 8 rheumatologists participated in both rounds 1 and 2
  • 17 new rheumatologists participated in rounds 2
  • Most of the attrition was from nephrology ( #NephJC occurring at same time as session 2, and “other” unidentifiable participants)

For the full 24 hours, there were 518 total tweets – 387 unique tweets and 117 RTs

  • Compared to round 1 – very similar: 506 total tweets – 410 unique tweets and 96 RTs

Of the 46 participants, the top 10 tweeters accounted for 75% of the total tweets

Session 1 (3pm EST)

  • 23 participants (11 Europe, 12 Americas)
  • 6 people participated again in session 2 (9pm EST)
  • There were 188 total tweets – 160 unique tweets and 22 RTs
  • Eli (@emilosla), our invited author, squeezed of 44 unique tweets!

Session 2 (9pm EST)

  • 17 participants (14 Americas, 1 India, 1 Australia, 1 unknown)
  • There were 240 total tweets – 189 unique tweets and 51 RTs

Of the 6 people who participated in both of the live one hour sessions, which included both moderators, they were pretty enthusiastic tweeters accounting for 43% of the total tweets for session 1 and 75% of the tweets from session 2

The 6 people were:

Symplur metrics from session 1:


Symplur metrics from session 2:


Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis


After a successful launch of RheumJC last month, we are pleased to announce our second International Twitter-based Rheumatology Journal Club which will occur on Tuesday, March 3rd. Like before, there will be two one-hour “live chats”, the first being at 8pm GMT (3pm EST) and the second later that evening at 2am GMT (9pm EST). We hope these sessions will accommodate a global audience, but in case you cannot join during these times, the session will last for a full 24 hours in an asynchronous format so that anyone who wants to participate can. The hashtag for the journal club will again be #rheumjc. We will conclude at 8pm GMT on March 4th with a summary of the entire session. The two one-hour live chats will be moderated by members of the RheumJC development team.

The article chosen for our this journal club is titled “Rituximab for the treatment of relapses in antineutrophil cytoplasmic antibody-associated vasculitis” by Miloslavsky, et al, published in the November 2014 edition of Arthritis & Rheumatology, Volume 66, Issue 11, pages 3151–3159.

The Wiley publishing group has graciously agreed to make the article available open-access beginning now and lasting through March 6th. Click here to access the article:–42053.1663773148

We are also extremely pleased to announce that the principal author of this manuscript, Dr. Eli Miloslavsky (@emilosla), will participate in the 8pm GMT (3pm EST) live session to answer any questions you may have about the article. Dr. Miloslavsky is a rheumatologist at Massachusetts General Hospital, an Instructor of Medicine at Harvard Medical School and the co-founder of the Vasculitis and Glomerulonephritis Center.

If you are participating for the first time, please read the section called getting started to get some tips on how to make the most of this session and not get too bogged down. Some additional pointers:

  1. Please remember to try to stay on topic whenever possible
  2. Be polite and courteous
  3. Do not violate HIPAA

As always, we welcome suggestions for future articles for discussion. Please send your suggestions by Direct Message on Twitter to @RheumJC or email us at